December 15, 2008

News on metastatic breast cancer

This might be the right week to change treatments. The annual San Antonio Breast Cancer Symposium
just ended and it's been in the news.

Just look at some of the posters that were presented. These are only a few of the things that may benefit me in the future --
Effective metabolic intervention of breast cancer progression and metastasis

A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study

All-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): latest results of a multicenter, international phase II trial with a median follow-up of 37.7 months

High dose estrogen as a salvage hormonal strategy for highly refractory metastatic breast cancer (MBC): "back to the future"

SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results

The one featuring high dose estrogen has received a lot of press. Read this CNN article for more.

1 comment:

  1. stunning news!
    sometimes i think the entire medical thing is in a quagmire of jargon!

    thanks for pointing our a bit sunshine...
    i saw capectabine a couple of times.